Strong Domestic Inflation Data Push Down Australian Shares
Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate
Nyrada Raises AU$1.8 Million via Placement
Significant Results for Nyrada's Brain Injury Treatment
Nyrada NYR-BI03 Trial Success Heralds Breakthrough in Stroke and Brain Injury Treatment
Stocks of the Hour: Nyrada Inc, Bastion Minerals, Global Oil & Gas
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%
Australian Shares Flat as June Unemployment Rate Remains at 3.5%
Nyrada Halves Director Fees; Shares Jump 37%
Nyrada (ASX:NYR) Launches in Vitro Studies for Brain Injury Program
No Data